Advanced chemotherapy-resistant ovarian cancer has a poor prog nosis, thus requiring new
therapeutic modalities. Acomplete clinical remission, using two cycles of 131l-labeled …

Objectives. Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen
(CEA), and the plasma CEA level is frequently elevated in patients with advanced stage and …

This is a preliminary study to evaluate the utility of using the monoclonal antibody (CO-125)
labeled with indium-111 to image recurrences of ovarian cancer. This technique has been …

Radioimmundetection (RID) using anti-CA 125 antibodies proved to be a valuable tool in the
follow-up of metastasizing ovarian cancer. Sensitivity, specificity, and accuracy were high …

Background A progressive rise in serum CA 125 concentration during follow-up monitoring
of ovarian cancer after treatment of primary tumor is suggestive of a recurrence. Patients and …

Purpose: This study was conducted to determine whether the cytotoxic agent cisplatin
(CDDP), also known as a radiosensitizer, can improve the efficacy of the 131I-labeled …

131I labelled F (ab') 2 fragments of monoclonal antibodies against CA 19-9 and CEA
(“radioimmunococktail” IMACIS 1) were used in a prospective study (n= 60 patients) and in a …

The murine monoclonal antibody (mAb) 145–9 recognizes an epitope present on CA125 but
different from the epitope defined by the mAb OC125. To evaluate the clinical usefulness of …

MATERIALSAND METhODS Padents Twelve patients with epitheial ovarian cancer
participated in a Phase I/il clinical trial of intraperitoneal administration of@ ÂY HMFG1-CITC …

Murine monoclonal antibody 196-14 recognizes the ovarian-cancer-associated antigen CA
125, but the epitope it recognizes is different from that of monoclonal antibody OC125. We …